About the study
Working title: Group Study — Psilocybin for a Psychiatric Condition (TBD). What we can share now: a group-based model, non-directive support, in person at Yale. Still being finalised: the target condition; eligibility; design, dosing and group structure; timeline and compensation.
This study is in protocol development. It is not open for enrollment and there is nothing to apply to. Registering interest does not enroll you and does not guarantee eligibility.
Is this study a fit?
The study team makes the final decision after screening. Final eligibility is determined in clinical screening, never by this page.
Not yet determined. The target condition has not been set. [confirm]
Study team
Meet the teamStudy facts
Sponsor: Yale University
Contact & location
Subscribe to this study
We will email you when this study opens and when results are published. Nothing else.
Not open yet — and not yet an application.
Prefer a hold with your name on it? Leave early interest and we will ask for you when this opens. Several studies are taking inquiries today — sign up for an intake call.
Clinicians: get an email when this study starts taking inquiries, or ask if a kind of patient is in scope.
Contact the study team
- Phone
- (203) 444-1795
- Location
- Enact Research Collaborative
40 Temple St., 4th Floor, Suite 4C
New Haven, CT 06510